

Martinez I¹, Barrios V², Pallares V³, Campuzano R⁴, Castellanos M⁵, Gomez Cerezo J⁶, Egocheaga I⁷, Games JM⁸, Morant Talamante N⁹, Rodriguez Barrios JM⁹, Sicras-Mainar A¹⁰, Pérez Román I¹⁰, Parrondo García FJ⁹, Mostaza JM¹¹

¹Son Spases University Hospital, Palma de Mallorca, Spain, ²Ramon Cajal University Hospital, Madrid, M, Spain, ³Unión de Mutuas, Castellón, Spain, ⁴Alcorcón Foundation University Hospital, Alcorcón, Spain, ⁵A Coruña University Hospital & Biomedical Research institute, A Coruña, Spain, ⁶Infanta Sofia University Hospital, Madrid, Spain, ⁷Clinic Centre Isla de Oza, Madrid, Spain, ⁸Son Llazer University Hospital, Palma de Mallorca, Spain, ⁹Novartis Spain, Barcelona, M, Spain, ¹⁰Atrys Health, Barcelona, Spain, ¹¹La Paz University Hospital, Madrid, Spain

INTRODUCTION

- Ischemic heart disease angina and acute myocardial infarction (AMI) are one of the main causes of morbidity and mortality in developed countries and entails a high resources consumption and costs for health systems¹⁻³.
- The risk of suffering future CV events (ASCVD)and the consequent consumption of resources is increased in those patients who have suffered a previous AMI^{4,5}.
- In Spain, there is little evidence available on the administration of lipid-lowering treatments in clinical practice and their effectiveness in patients with ASCVD and hypercholesterolemia⁶.
- Dimensioning the magnitude of ASCVD can help inform decision-making in Health Systems

OBJECTIVE

The aim of this study was to estimate the average annual cost per patient with a new diagnosis or new episode of angina and AMI.

METHODS

- A retrospective observational study of the electronic medical records of patients from the BIG-PAC® database (patients from 7 integrated areas of 7 Spanish Regions; n=1.8 million) was carried out.
- Patients with a new/recurrent Ischemic heart disease episode between 1/1/2017 and 12/31/2018 were included.
- Direct healthcare costs (DHCC) were calculated from the consumption of resources during follow-up (two years from diagnosis) and the mean of the Regions official published tariff.
- The indirect non-health costs (INHCC) associated with the loss of productivity were determined.
- All costs were updated to €2021.

RESULTS

- The following figures and tables show: the demographic features and follow-up events (table 1); the resource consumption - hospital admissions and visits (figures 1 & 2) and diagnostic tests (figures 3 & 4); the direct healthcare costs (table 2) and non-healthcare costs (table 3); and a cost summary (table 4).

Table 1. Demographics features and follow-up events

	Angina	IAM	Total
n	6,794	5,556	12,350
Age (years) (mean [SD])	69.6 [11.5]	68.5 [12.3]	
Gender (Male %)	4,278 (63%)	3,324 (59.8%)	7,602 (61.6%)
Follow-up events			
New ASCVD event	2,134 (31.4%)	1,378 (24.8%)	3,512 (28.4%)
Deaths - n (%)	500 (7.4%)	298 (5.4%)	798 (6.5%)

Figure 1: Resource consumption: Visits (% Patients)




Figure 2: Resource consumption: Visits (average per patient)




Figure 3: Resource consumption: Diagnostic (% Patients)




Figure 4: Resource consumption: Diagnostic (average per patient)




Table 2. Direct healthcare costs (average cost per patient)

	Angina		IAM	
	Year 1	Year 2	Year 1	Year 2
Average cost per patient	9,512 €	8,566 €	8,679 €	7,548 €
Main drivers of cost				
Therapeutic procedures	4,191 €	4,157 €	3,883 €	3,805 €
Hospitalizations	1,702 €	1,509 €	1,304 €	1,003 €
Medication	1,239 €	1,199 €	1,315 €	1,204 €

Table 3. Non-healthcare costs (average cost per patient)				
	Angina		IAM	
	Year 1	Year 2	Year 1	Year 2
Sick leave ***	1,208 €	1,130 €	1,306 €	1,149 €
Permanent disability****	404 €	412 €	403 €	411 €
Premature deaths *****	354 €	735 €	252 €	552 €
Non-healthcare costs	1,966 €	2,277 €	1,961 €	2,112 €

** Includes coronary artery bypass(percutaneous), angioplasty and endarterectomy/thrombectomy; ** Includes echocardiogram, stress test and cardiac holter; *** Sick leave due to temporally disability in the working population (under 65 y.o.); **** Permanent disability in the working population (under 65 y.o.); ***** Difference between the age of death and the retirement age in Spain.*

CONCLUSION

Patients with ischemic heart disease have a high mortality and represent a considerable social and healthcare cost. Developing preventive programs including primary care, cardiac rehabilitation and controlling cardiovascular risk factors could help reduce mortality and cost for the Spanish National Health System. Infarction (AMI) are one of the main causes of morbidity and mortality in developed countries and entails a high resources consumption and costs for health systems. The risk of suffering future CV events and the consequent consumption of resources is increased in those patients who have suffered a previous AMI..

REFERENCES

1.Mortalidad cardiovascular en España en 2020 - Sociedad Española de Cardiología (secardiologia.es) Último acceso: 26/04/2022. 2. World Health Orhanization (WHO) [Internet]. Cardiovascular diseases (CVDs). Updated June 2021. Disponible en: Cardiovascular diseases (CVDs) (who.int). Último acceso: 26/04/2022 3. Datos de España. Timmis A, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020 Jan 1;41(1):12-85.. 4. Lindh M et al., Eur Heart J Qual Care Clin Outcomes. 2019;5(3):225-32. 5. Estrategia en Salud Cardiovascular del Sistema Nacional de Salud (ESCAV). Ministerio de Sanidad. Marzo de 2022. 6. El abordaje de la hipercolesterolemia en España. Mapeo de políticas y diagnóstico de situación por CCAA. Disponible en: https://blogs.deusto.es/dbshealth/wp-content/uploads/sites/60/2018/01/EnChol_Mapeo-de-pol%C3%ADticas_15012018.pdf.

ACKNOWLEDGEMENT

This Study was financially supported by Novartis

EE84

ECONOMIC EVALUATION
CARDIOVASCULAR DISORDERS

ISPOR Europe 2022

6-9 November 2022
Vienna, Austria and Virtual
#ISPOREurope

